Clinical Trial Update: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated oxaliplatin in patients with relapsed or refractory non-Hodgkin lymphoma across multiple subtypes and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Malt
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 2 | Status: COMPLETED